Aquestive Therapeutics Inc (AQST)
Aquestive Therapeutics, Inc. is a NASDAQ-listed common stock company focused on pharmaceutical products and technologies in the United States and international markets. Its marketed portfolio includes Libervant for seizure treatment, Suboxone for opioid dependence, EMYLIF for riluzole delivery, ONDIF for ondansetron delivery, SYMPAZAN for seizures associated with a rare form of epilepsy, KYNMOBI for apomorphine delivery, and AZSTARYS for ADHD in patients age 6 years and older. The company also is developing Anaphylm, an epinephrine sublingual film in phase 3 trials for emergency treatment of allergic reactions including anaphylaxis, and AQST-108, a topical gel in phase 2 development for alopecia areata. In addition, Aquestive develops PharmFilm technology for patients with certain central nervous system disorders and the Adrenaverse epinephrine prodrug platform. Founded in 2004, the company is headquartered in Warren, New Jersey.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-AQST
|
$4.96
|
0.3% Upside
|
Fair
|
$9.33
|
88.6% Upside
|
Bargain
|
Fair
|
0.0%
|
November 9, 2026
|
11.5x
|
621.3 M
|
581.8 M
|
8.7%
|
91.3%
|
-3.1
|
58.7%
|
